4Front Ventures (FFNTF) 10-Q15 May 232023 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2023	May 15, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	000-56075
Entity Registrant Name	4Front Ventures Corp.
Entity Incorporation, State or Country Code	A1
Entity Tax Identification Number	83-4168417
Entity Address, Address Line One	5060 N. 40th Street
Entity Address, Address Line Two	Suite 120
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85018
City Area Code	602
Local Phone Number	633-3067
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		648,583,519
Entity Central Index Key	0001783875
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Class A Subordinate Voting Share
Document Information [Line Items]
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value
Trading Symbol	FFNTF
Security Exchange Name	NONE
ADR
Document Information [Line Items]
Title of 12(b) Security	Class A Subordinate Voting Shares, no par value
Trading Symbol	FFNT
Security Exchange Name	NONE

CONDENSED CONSOLIDATED INTERIM

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash	$ 4,628	$ 15,190
Accounts receivable, net	8,492	7,391
Other receivables	191	77
Current portion of lease receivables	3,855	3,810
Inventory	27,388	25,592
Prepaid expenses and other assets	1,514	1,207
Total current assets	46,068	53,267
Property, plant, and equipment, net	55,382	56,906
Lease receivables	5,242	5,611
Intangible assets, net	30,229	30,927
Goodwill	53,955	53,955
Right-of-use assets	137,002	138,451
Deposits	5,868	5,615
TOTAL ASSETS	333,746	344,732
Current liabilities:
Accounts payable	12,048	12,701
Accrued expenses and other current liabilities	11,653	14,265
Taxes payable	39,176	36,577
Current portion of contract liabilities	682	369
Current portion of lease liability	3,742	4,479
Current portion of notes payable and accrued interest	7,727	9,059
Total current liabilities	75,028	77,450
Convertible notes	15,122	14,843
Notes payable and accrued interest from related party	50,129	49,807
Long term notes payable	10,599	10,456
Long term accounts payable	1,362	1,362
Contract liabilities	2,000	2,000
Construction finance liability	16,000	16,000
Deferred tax liability	8,024	8,278
Lease liability	137,503	136,185
TOTAL LIABILITIES	315,767	316,381
SHAREHOLDERS' EQUITY
Subordinate Voting Shares (no par value, unlimited shares authorized, 643,416,275 shares issued and outstanding as of March 31, 2023 and December 31, 2022)	304,602	304,602
Additional paid-in capital	60,431	59,411
Deficit	(347,152)	(335,755)
Equity attributable to 4Front Ventures Corp.	17,881	28,258
Non-controlling interest	98	93
TOTAL SHAREHOLDERS' EQUITY	17,979	28,351
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 333,746	$ 344,732

CONDENSED CONSOLIDATED INTERI_2

CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (unaudited) - shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, shares issued (in shares)	643,416,275	643,416,275
Common stock, shares outstanding (in shares)	643,416,275	643,416,275

CONDENSED CONSOLIDATED INTERI_3

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
REVENUE
Revenue from sale of goods	$ 27,370	$ 23,083
Real estate income	3,006	2,965
Total revenues	30,376	26,048
Cost of goods sold	(19,388)	(12,594)
Gross profit	10,988	13,454
OPERATING EXPENSES
Selling and marketing expenses	7,038	5,109
General and administrative expenses	7,856	7,654
Depreciation and amortization	870	847
Equity based compensation	1,020	1,038
Total operating expenses	16,784	14,648
Loss from operations	(5,796)	(1,194)
Other income (expense)
Interest income	14	2
Interest expense	(3,196)	(2,620)
Change in fair value of derivative liability	0	1,300
Loss on litigation settlement	(3)	0
Other	655	56
Total other income (expense), net	(2,530)	(1,262)
Net loss before income taxes	(8,326)	(2,456)
Income tax expense	(3,066)	(3,438)
Net loss	(11,392)	(5,894)
Net income attributable to non-controlling interest	5	5
Net loss attributable to shareholders	$ (11,397)	$ (5,899)
Basic loss per share (in dollar per share)	$ (0.02)	$ (0.01)
Diluted loss per share (in dollar per share)	$ (0.02)	$ (0.01)
Weighted average number of shares outstanding, basic (in shares)	642,140,067	619,113,389
Weighted average number of shares outstanding, diluted (in shares)	642,140,067	619,113,389

CONDENSED CONSOLIDATED INTERI_4

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Total 4Front Ventures Corp. Shareholders' Equity	Share Capital	Additional Paid-In Capital	Deficit	Non-Controlling Interest
Beginning balance (in shares) at Dec. 31, 2021			594,181,604
Beginning balance at Dec. 31, 2021	$ 37,532	$ 37,460	$ 274,120	$ 52,197	$ (288,857)	$ 72
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued for NECC pursuant to acquisition (in shares			28,571,428
Shares issued for NECC pursuant to acquisition	17,689	17,689	$ 17,689
Share-based compensation	1,038	1,038		1,038
Conversion of notes to equity (in shares)			6,235,512
Conversion of notes to equity	3,122	3,122	$ 3,122
Shares issued with exercise of warrants (in shares)			88,659
Shares issued with exercise of warrants	50	50	$ 50
Net loss	(5,894)	(5,899)			(5,899)	5
Ending balance (in shares) at Mar. 31, 2022			629,077,203
Ending balance at Mar. 31, 2022	$ 53,537	53,460	$ 294,981	53,235	(294,756)	77
Beginning balance (in shares) at Dec. 31, 2022	643,416,275		643,416,275
Beginning balance at Dec. 31, 2022	$ 28,351	28,258	$ 304,602	59,411	(335,755)	93
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued for NECC pursuant to acquisition	0
Share-based compensation	1,020	1,020		1,020
Net loss	$ (11,392)	(11,397)			(11,397)	5
Ending balance (in shares) at Mar. 31, 2023	643,416,275		643,416,275
Ending balance at Mar. 31, 2023	$ 17,979	$ 17,881	$ 304,602	$ 60,431	$ (347,152)	$ 98

CONDENSED CONSOLIDATED INTERI_5

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (11,392)	$ (5,894)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,391	1,795
Equity based compensation	1,020	1,038
Change in fair value of derivative liability	0	(1,300)
Accretion of lease liability	2,030	1,513
Accretion of debt discount	92	0
Accrued interest on convertible debenture and interest	227	279
Accrued interest on notes payable	2,352	1,973
Interest accrued - lease receivable	324	208
Deferred taxes	(254)	(687)
Changes in operating assets and liabilities:
Accounts receivable, net	(1,101)	(2,309)
Other receivables	(114)	0
Prepaid expenses and other assets	(57)	153
Inventory	(1,796)	(3,823)
Accounts payable	(653)	0
Accrued expenses and other current liabilities	(2,612)	778
Contract liabilities	313	0
Taxes payable	2,599	3,651
Deposits	(253)	257
NET CASH USED IN OPERATING ACTIVITIES	(6,884)	(2,368)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash paid for asset acquisitions and business combinations, net of cash received	(250)	(24,998)
Proceeds from note receivable	0	98
Purchases of property and equipment	(170)	(1,109)
NET CASH USED IN INVESTING ACTIVITIES	(420)	(26,009)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance of construction financing liability	0	16,000
Proceeds from the exercise of warrants	0	50
Repayments of notes payable	(3,259)	(1,616)
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES	(3,259)	14,434
NET DECREASE IN CASH	(10,563)	(13,943)
CASH, BEGINNING OF PERIOD	15,190	22,581
CASH, END OF PERIOD	4,627	8,638
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid for interest	89	1,569
Cash paid for income taxes	722	1,110
Non-cash investing and financing activities:
Issuance of equity for business combinations	0	17,689
Exchange of convertible debt to equity	0	3,122
Issuance of equity to acquire property and equipment	0	15,238
Change in right-of-use assets and lease liabilities	$ 0	$ 77

Nature of Operations

Nature of Operations	3 Months Ended
Nature of Operations	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	NATURE OF OPERATIONS 4Front Ventures Corp. (“4Front” or the “Company”) exists pursuant to the provisions of the British Columbia Corporations Act. The Company operates the business through two segments: THC Cannabis and CBD Wellness. As of March 31, 2023, the Company's THC Cannabis segment consists o f six dispensaries and seven production and cultivation facilities across Illinois, Michigan, Massachusetts, and California. Also, as part of its THC Cannabis segment, the Company leases real estate and sells equipment, supplies, and intellectual property to cannabis producers in the state of Washington. The Company’s CBD Wellness segment sells non-THC hemp derived products across the United States. The unaudited condensed consolidated interim financial statements include the accounts of 4Front and all entities in which the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The Company has prepared these statements pursuant to the rules and regulations of the United States Securities and Exchange Commission (SEC) and U.S. GAAP. Certain information related to the organization, significant accounting policies, and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed, or omitted. In the opinion of management, the financial statements include all adjustments necessary for the fair presentation of the results of the interim periods presented. All adjustments are of a normal recurring nature, except as otherwise noted below. Operating results for interim periods are not necessarily indicative of results you can expect for a full year. These financials should be read in conjunction with our audited consolidated financial statements and notes thereto appearing in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Going Concern As of March 31, 2023, the Company had cash and cash equivalents of $4.6 million and working capital deficit of $29.0 million. The Company incurred net losses of $11.4 million and $5.9 million for the three months ended March 31, 2023 and 2022, respectively. The conditions described above raise substantial doubt with respect to the Company’s ability to meet its obligations for at least one year from the issuance of these consolidated financial statements, and therefore, to continue as a going concern. The Company plans to continue to fund its operations through cash generated from sales and is deploying its capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are being utilized for capital expenditures and improvements in existing facilities, product development and marketing, as well as customer, supplier and investor and industry relations. The Company has raised capital as needed, however there is no guarantee the Company will be able to continue to raise funds in the same manner it has historically. Management's Estimates and Assumptions The preparation of the Company’s financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations. We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary. Actual results may differ from these estimates. The most critical and subjective areas are discussed in detail in the notes in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022. There have been no changes to the Company's accounting policies since the Annual Report. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the consolidated balance sheet and the consolidated statement of cash flows as of and for the year ended December 31, 2022. The reclassifications on the consolidated statement of operations for the year ended December 31, 2022 had no effect on revenues and net loss for the year ended December 31, 2022. New Accounting Pronouncements Accounting Standard Updates Issued but Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820) ". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

Inventory

Inventory	3 Months Ended
Inventory	Mar. 31, 2023
Inventory Disclosure [Abstract]
Inventory	INVENTORY The Company’s inventories are summarized in the table below: March 31, 2023 December 31, 2022 Raw materials - unharvested cannabis $ 3,379 $ 2,688 Raw materials - harvested and purchased cannabis 7,760 7,956 Packaging and other non-finished goods 2,092 2,468 Work in process - manufactured and purchased extracts 3,980 3,635 Finished goods 10,177 8,845 Total inventory $ 27,388 $ 25,592

Property Plant and Equipment

Property Plant and Equipment	3 Months Ended
Property Plant and Equipment	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT, AND EQUIPMENT Property, plant, and equipment and related depreciation are summarized in the table below: March 31, 2023 December 31, 2022 Land $ 774 $ 774 Buildings & improvements 13,995 13,784 Construction in process 241 82 Furniture, equipment & other 19,000 19,296 Leasehold improvements 36,291 36,287 Total $ 70,301 $ 70,223 Less: accumulated depreciation (14,919) (13,317) Total property, plant, and equipment, net $ 55,382 $ 56,906 Depreciation expense for the three months ended March 31, 2023 and 2022 was $1.7 million and $1.2 million, respectively, of which $1.5 million and $0.9 million, respectively, is included in cost of goods sold. Unless specifically excluded in the LI Lending note, all property, plant, and equipment is secured by LI Lending as collateral on the LI Lending note (Note 7). On October 27, 2022, the Company amended its lease agreement for the Company’s facility located in Matteson, Illinois by creating an option to increase the tenant improvement allowance for the facility between $15.0 million and $19.9 million. On November 10, 2022, the Company exercised its option and entered into a Second Amendment to Lease Agreement, increasing the tenant improvement allowance under the lease by $19.9 million; extending the term of the lease to 20 years after the amendment; increasing the base rent by $0.2 million per month (abated until April 1, 2023); and increasing the security deposit by $2.2 million, to be funded pro rata out of draws on the tenant improvement allowance.

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended
Intangible Assets and Goodwill	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill	INTANGIBLE ASSETS AND GOODWILL Intangible Assets Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Compete Agreements Know-How Tradenames and Trademarks Total Gross Carrying Amount, March 31, 2023 and December 31, 2022 $ 25,662 $ 2,900 $ 249 $ 9,700 $ 2,022 $ 40,533 Accumulated Amortization, December 31, 2022 $ — $ (2,393) $ (249) $ (6,628) $ (336) $ (9,606) Amortization Expense — (145) — (485) (68) (698) Accumulated Amortization, March 31, 2023 $ — $ (2,538) $ (249) $ (7,113) $ (404) $ (10,304) During the three months ended March 31, 2023, the Company entered into an agreement to acquire a dispensary license from Euphoria, LLC. Refer to Note 5 for further details on the transaction. Impairment of Intangible Assets and Goodwill Goodwill as of March 31, 2023 is related to the THC Cannabis segment in which there is no accumulated impairment within this segment. Goodwill related to the CBD Wellness segment has an accumulated impairment charge of $13.4 million, which represented the entire balance and occurred during the year ended December 31, 2020. As of March 31, 2023 and December 31, 2022, all goodwill and intangibles are attributable to the THC Cannabis segment. The balance of goodwill remained unchanged at $54.0 million as of March 31, 2023 and December 31, 2022. Goodwill and infinite lived assets are assessed on an annual basis for impairment, or more frequently, if circumstances indicate an impairment to the carrying value may have occurred. As of March 31, 2023, the Company believes the carrying amounts of the long-lived assets, including finite-lived intangible assets (licenses), are recoverable and there were no events or circumstances that indicated impairment. However, if adverse events were to occur or circumstances were to change indicating the carrying amount of such assets may not be fully recoverable, the assets would be reviewed for impairment.

Asset Acquisitions

Asset Acquisitions	3 Months Ended
Asset Acquisitions	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Asset Acquisitions	ASSET ACQUISITIONS Euphoria, LLC On March 27, 2023, the Company entered into a Membership Interest Purchase Agreement to acquire 100% of the issued and outstanding equity interests in Euphoria, LLC ("Euphoria") for a total purchase price of $4.5 million to be paid in cash, promissory notes, and Class A Subordinate Voting Shares. Euphoria holds a conditional adult use dispensary license in the state of Illinois which shall convert to a state license upon regulatory approval. The transfer of the license is subject to regulatory approval. Of the total purchase price of $4.5 million, the Company has paid $0.3 million in cash as of March 31, 2023. In certain events as defined in this agreement, such as, but not limited to the inability to obtain regulatory approval, all consideration paid by the Company to the sellers are refundable. Subsequent to the balance sheet date, the Company issued 2,308,952 Class A Subordinate Voting Shares valued at $0.4 million based on the closing stock price of the SVS on the issuance date. The remaining consideration will be due upon regulatory approval at the closing date. In the event of termination by the Company under certain circumstances, the Company shall pay a breakup fee of $3.5 million to the sellers, less any potion of the purchase price already paid. Conversely, in the event of termination by the sellers under certain circumstances, the sellers shall pay a breakup fee of $3.5 million to the Company.

Leases

Leases	3 Months Ended
Leases	Mar. 31, 2023
Leases [Abstract]
Leases	LEASES The Company as a Lessor: Lease income for operating and direct financing leases for the periods presented are as follows: Three Months Ended March 31, 2023 2022 Real estate income: Operating leases $ 2,384 $ 2,273 Direct financing leases 622 692 Total real estate income $ 3,006 $ 2,965 The Company leases buildings in Olympia, Washington, Elk Grove, Illinois and Commerce, California that are subleased or partly subleased to a third party. The subleases are classified as operating leases under ASC 842. The underlying assets are presented in the condensed consolidated balances sheets as follows: March 31, 2023 December 31, 2022 Right-of-use assets $ 36,060 $ 36,596 Current portion of lease liability $ 1,610 $ 1,568 Long-term portion of lease liability $ 31,629 $ 31,904 The Company also leases a building in Elma, Washington that is subleased to a third party. This sublease is classified as a finance lease. A reconciliation of the lease receivables is as follows: March 31, 2023 December 31, 2022 Balance, December 31, 2022 $ 9,421 $ 10,378 Interest 621 2,673 Lease payments received (945) (3,630) Balance, March 31, 2023 9,097 9,421 Less current portion (3,855) (3,810) Long-term lease receivables $ 5,242 $ 5,611

Notes Payable and Convertible N

Notes Payable and Convertible Notes	3 Months Ended
Notes Payable and Convertible Notes	Mar. 31, 2023
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes	NOTES PAYABLE AND CONVERTIBLE NOTES The Company’s notes payable and convertible notes are as follows: Terms March 31, 2023 December 31, 2022 Secured promissory notes dated May 10, 2019, as subsequently amended, with a related party drawn in two tranches: (i) $35.0 million bearing interest at 12.75% and (ii) $10.0 million bearing interest at 14.75%, which mature on May 10, 2024 $ 50,129 $ 49,807 Convertible promissory note dated October 6, 2021, which mature on October 6, 2024 and bear interest at a rate of 6% per annum 15,122 14,843 Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 3,721 3,554 Promissory note issued for the acquisition of NECC due January 7, 2023 at 10% per annum — 519 Promissory note issued for the acquisition of Island due October 25, 2026 at 6% per annum 10,579 10,431 Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months (1) 2,254 3,230 Unsecured promissory note due September 30, 2023, monthly interest payments at 12% per annum 1,730 1,730 Various 43 51 Total Notes Payable and Convertible Notes $ 83,577 $ 84,165 (1) The Company is in default of the secured promissory note as of March 31, 2023. Management is renegotiating terms of the promissory note as of the date of these consolidated financial statements. LI Lending LLC On May 10, 2019, the Company entered into a loan agreement with LI Lending LLC, a related party, for $50.0 million, of which $43.0 million was drawn as of March 31, 2023 in two amounts: (i) $35.0 million bearing interest at a rate of 10.25% and (ii) $10.0 million bear interest at a rate of of 12.25%. The loan matures on May 10, 2024 upon the Company shall pay an exit fee of 20% of the remaining principal balance. In April 2020, the loan was amended to release certain assets previously held as collateral and to make principal prepayments totaling $2.0 million applied to the initial $35.0 million amount, decreasing the principal balance to $33.0 million. In December 2020, the loan was amended to increase the interest rate by 2.5% of which payments of the incremental interest were paid-in-kind until January 1, 2022. The Company was still required to make interest-only payments monthly of 10.25% on the initial $33.0 million and 12.25% on the final $10.0 million of the loan until January 1, 2022, when monthly interest rates were increased to 12.75% for the initial $35.0 million and 14.75% for the final $10.0 million for the remaining term. For the three months ended March 31, 2023 and 2022, the Company recognized accrued interest expense of $1.9 million and $1.9 million, respectively, on the related party loan. During the three months ended March 31, 2023 and 2022, the Company made $1.6 million and $1.5 million, respectively, in payments of principal and interest to the related party. See Note 12 for further discussion of this related party transaction. October 2021 Convertible Note On October 6, 2021, the Company entered into a convertible promissory note for $15.0 million that is exercisable into Class A Subordinate Voting Shares for $1.03 per share at any time at the option of the holder. The notes bear interest at 6% per annum and mature on October 6, 2024 upon which any remaining balance is payable in cash. All accrued and unpaid interest is payable in cash on an annual basis beginning on October 6, 2022. As of March 31, 2023, payments of principal and interest totaling $1.1 million have been made for this loan. As of March 31, 2023 and December 31, 2022, the unamortized discount balance related to the October 2021 Convertible Note was $0.3 million and $0.4 million, respectively, with a remaining amortization period of 1.5 an d 1.75 years, respectively. For the three months ended March 31, 2023 and 2022 , the Company recognized interest expe nse of $0.2 million an d $0.3 million, respectively, and accretion of debt discount of $0.1 million and $0.1 million , respectively, related to the October 2021 Convertible Note.

Shareholders' Equity

Shareholders' Equity	3 Months Ended
Shareholders' Equity	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Shareholders' Equity	SHAREHOLDERS' EQUITY The Company has authorized an unlimited number of Class A Subordinate Voting Shares (“SVS”) and Class C Multiple Voting Shares (“MVS”), all with no par value. All share classes are included within share capital in the consolidated statements of shareholders’ equity on an as- converted basis. Each share class is entitled to notice of and to attend any meeting of the shareholders, except a meeting of which only holders of another particular class of shares will have the right to vote. All share classes are entitled to receive dividends, as and when declared by the Company, on an as-converted basis, and no dividends will be declared by the Company on any individual class unless the Company simultaneously declares or pays dividends on all share classes. No subdivision or consolidation of any share class shall be made without simultaneously subdividing or consolidating all share classes in the same manner. Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Voting Shares Class C Multiple Voting Shares Total Balance, December 31, 2022 642,140,067 1,276,208 643,416,275 Balance, March 31, 2023 642,140,067 1,276,208 643,416,275 Class A Subordinate Voting Shares Holders of Class A Subordinate Voting Shares are entitled to one vote in respect of each SVS. Class C Multiple Voting Shares Holders of Class C Multiple Voting Shares are entitled to 800 votes in respect of each MVS. One MVS can convert to one SVS but are not convertible until the aggregate number of MVS held by the Initial Holders (being the MVS holders on their initial issuance) are reduced to a number which is less than 50% of the aggregate number of MVS held by the Initial Holders on the date of completion of the business combination with Cannex. Series Shares outstanding as of March 31, 2023 Class A - Subordinate Voting Shares 642,140,067 Class C - Multiple Voting Shares 1,276,208 643,416,275

Warrants

Warrants	3 Months Ended
Warrants	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Warrants	WARRANTS A reconciliation of the beginning and ending balance of share purchase warrants outstanding is as follows: Number of Warrants Weight-Average Exercise Price Balance, December 31, 2022 6,352,278 $ 0.82 Expired (2,227,303) 0.67 Balance, March 31, 2023 4,124,975 $ 0.89 As of March 31, 2023, the Company had the following warrants outstanding: Warrants Outstanding Exercise Price Expiration Date 2,999,975 $ 1.00 April 13, 2024 625,000 * C$ 0.80 October 6, 2024 500,000 * C$ 0.80 October 6, 2025 4,124,975 *Represents warrants that were exercisable as of March 31, 2023.

Share-Based Compensation

Share-Based Compensation	3 Months Ended
Share-Based Compensation	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	SHARE-BASED COMPENSATION The Company adopted two equity incentive plans where the Company may grant Class A stock options. Under the terms of the plans, the maximum number of stock options which may be granted are a total of 10% of the number of shares outstanding assuming conversion of all shares to SVS. The exercise price for stock options issued under the plans will be set by the Compensation Committee of the Board of Directors but will not be less than 100% of the fair market value of the Company’s shares on the grant date. Stock options have a maximum term of 10 years from the date of grant. Stock options vest at the discretion of the Board. As of March 31, 2023, the Company had 51,999,458 options exercisable and 64,168,626 options outstanding, with exercise prices ranging from C$0.10 to C$1.63. The following table summarizes the Company’s stock option activity and related information: Number of Options Weighted Average Price CAD$ Weighted Average Years Balance, December 31, 2022 75,626,960 $ 0.86 3.46 Forfeited/Expired (11,458,334) $ 0.65 — Balance, March 31, 2023 64,168,626 $ 0.83 2.94 During the three months ended March 31, 2023 and 2022, the Company recognized share-based compensation of $1.0 million and $1.0 million. No options were granted for the three months ended March 31, 2023. In determining the amount of equity-based compensation during the period ended March 31, 2022, the Company used the Black-Scholes option pricing model to establish the fair value of options granted with the following key assumptions: Three Months Ended March 31, 2022 Risk-Free Interest Rate 2.42 % Expected Life 5.00 years Expected Annualized Volatility 71.30 % Forfeiture rate — % Expected Dividend Yield — %

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES The following table summarizes the Company's income tax expense: For the Three Months Ended March 31, 2023 2022 Net loss before income taxes $ (8,326) $ (2,456) Income tax expense $ (3,066) $ (3,438) The Company has computed its provision for income taxes under the discrete method which treats the year-to-date period as if it were the annual period and determines the income tax expense or benefit on that basis. The discrete method is applied when application of the estimated annual effective tax rate is impractical because it is not possible to reliably estimate the annual effective tax rate. At this time, there is a high degree of uncertainty in estimating the Company’s annual pre-tax income and significant non-deductible expenses so the Company cannot reliably estimate the annual effective tax rate. Due to its cannabis operations, the Company is subject to the limitations of Internal Revenue Code (“IRC”) Section 280E. Under IRC Section 280E, the Company is only allowed to deduct expenses directly related to sales of its cannabis products. This results in permanent differences between ordinary and necessary business expenses deemed non-allowable under IRC Section 280E for the Company's expenses related to its plant-touching cannabis operations. The effective tax rate for the three months ended March 31, 2023 varies from the three months ended March 31, 2022 primarily due to the change in nondeductible expenses under IRC Section 280E as a proportion of pre-tax loss during the period. The Company incurs expenses that are not deductible due to IRC Section 280E limitations which results in significant permanent book-to-tax differences that may not necessarily correlate with pre-tax income or loss. The Company files income tax returns in the US and various state jurisdictions and is subject to examination of its income tax returns by tax authorities in these jurisdictions who may challenge any item on these returns. The corporate statute of limitations for these jurisdictions remains open for the 2019 tax year to the present.

Related Parties

Related Parties	3 Months Ended
Related Parties	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Parties	RELATED PARTIESLI Lending LLC Linchpin Investors LLC (“Linchpin”), a subsidiary of the Company, and LI Lending LLC (“LI Lending”) entered into a Construction Loan Agreement dated May 10, 2019, as amended, whereby Linchpin received an up-to $50.0 million loan from LI Lending, of which $43.0 million was drawn as of March 31, 2023 . Mr. Gontmakher, the CEO of the Company, and Roman Tkachenko, a director of the Company, each hold a 14.28% ownership interest in LI Lending. The loan matu

Contingencies

Contingencies	3 Months Ended
Contingencies	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	CONTINGENCIES (a) Cannabis Industry While marijuana is legal under the laws of several U.S. states (with varying restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug, whether for medical or recreational use. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. As such, there is an inherent risk related to the federal government’s position on cannabis. There is additional risk associated with the Company’s business in cannabis that third-party service providers could suspend or withdraw services and regulatory bodies could impose certain restrictions on the issuer’s ability to operate in the U.S. As of March 31, 2023 , Company has not estimated a potential liability related to the possible enforcement of laws against the medical cannabis industry. (b) Legal Matters From time to time, the Company may be involved in certain disputes arising in the ordinary course of business. Such disputes, taken in the aggregate, are not expected to have a material adverse effect on the Company. There are also no proceedings in which any of the Company’s directors, officers, or affiliates is an adverse party or has a material interest adverse to the Company’s interest. On January 26, 2022, Savills, Inc. sued the Company in the U.S. District Court for the Southern District of New York. That lawsuit alleged the Company had breached an alleged agreement with Savills under which the Company was allegedly required to pay Savills a percentage of savings realized under certain incentive programs offered in some jurisdictions, which Savills would assist the Company in obtaining. Savills claimed damages of approximately $19.4 million in connection with its claim that it obtained benefits for the Company allegedly valued at over $129.0 million. The Company denied these allegations, denied the Company had obtained such benefits, disputed Savills’ characterization of the facts, and denied liability. The Company filed a counterclaim against Savills alleging breach of contract by Savills. On August 3, 2022, the parties reached a confidential settlement in principle and agreed to dismissal of all claims, which was finalized on September 12, 2022 and required the Company to pay $0.25 million in five monthly installments beginning in October 2022. In addition to this initial payment, there is a portion of the settlement that is contingent on future tax savings. As of March 31, 2023, this additional contingent amount is not reasonably estimable.

Financial Instruments and Finan

Financial Instruments and Financial Risk Management	3 Months Ended
Financial Instruments and Financial Risk Management	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Financial Instruments and Financial Risk Management	FINANCIAL INSTRUMENTS AND FINANCIAL RISK MANAGEMENT The fair value of the Company’s cash, accounts receivable, other receivables, accounts payable and accrued expenses approximates carrying value due to their short-term nature. The Company’s notes receivable, lease receivables, derivative liabilities, convertible notes payable, and notes payable approximate fair value due to the instruments bearing market rates of interest. These measurements were identified as Level 1 measurements, due to the proximity of fair value to carrying values. The fair value of stock options granted were estimated based on a Black-Scholes model. The estimated fair value of the derivative liabilities, which represent warrants classified as liabilities, represent Level 3 measurements. In November 2022, the warrants issued in connection with the November 2020 private placement had expired unexercised and, accordingly, the balance of derivative liabilities was nil. As of March 31, 2023 and December 31, 2022, the Company did not have any derivatives valued within the fair value hierarchy. For the three months ended March 31, 2022, changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3) were as follows: For the Three Months Ended March 31, 2022 Balance, beginning of period $ 3,502 Gain on fair value of derivative liability (1,300) Balance, end of period $ 2,202 There were no transfers between fair value levels for the three months ended March 31, 2023 and the year ending December 31, 2022. (a) Financial Risk Management The Company is exposed in varying degrees to a variety of financial instruments related risks. The Company's board of directors mitigate these risks by assessing, monitoring and approving the Company’s risk management processes. (b) Credit Risk Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, accounts receivable, lease receivables, and other receivables. The risk to cash deposits is mitigated by holding these instruments with regulated financial institutions. Accounts receivable, lease receivables, and other receivables credit risk arises from the possibility that principal and interest due may become uncollectible. The Company mitigates this risk by managing and monitoring the underlying business relationships. The Company maintains cash with federally insured financial institutions. A s of March 31, 2023 and December 31, 2022 , the Company exceeded federally insured limits by $0.7 million and $10.1 million, respectively. The Company has historically not experienced any losses in such accounts. As of March 31, 2023 and December 31, 2022 , the Company held an immaterial amount of cash in a Canadian account that is denominated in C$. As of March 31, 2023 and December 31, 2022, the maximum credit exposure related to the carrying amounts of accounts receivable, other receivable, and lease receivables was $17.8 million and $16.9 million, respectively. (c) Liquidity Risk The Company manages liquidity risk through the management of its capital structure. The Company’s approach to managing liquidity is to raise sufficient capital to settle obligations and liabilities when due. The Company has raised capital as needed, however there is no guarantee the company will be able to continue to raise funds in the same manor it has historically. The Company has the following gross contractual obligations as of March 31, 2023, which are expected to be payable in the following respective periods: Less than 1 year 1 to 3 years 3 to 5 years Greater than 5 years Total Accounts payable and accrued liabilities $ 23,701 $ 1,362 $ — $ — $ 25,063 Convertible notes, notes payable and accrued interest 7,727 75,850 — — 83,577 Construction finance liability — 16,000 — — 16,000 Total $ 31,428 $ 93,212 $ — $ — $ 124,640 (d) Foreign Exchange Risk The Company is exposed to exchange rate fluctuations between United States and Canadian dollars. The Company’s share price is denominated in Canadian dollars. If the Canadian dollar declines against the United States dollar, the United States dollar amounts available to fund the Company through the exercise of stock options or warrants will be reduced. The Company also has bank accounts with balances in Canadian dollars. The value of these bank balances if converted to U.S. dollars will fluctuate. While the Company maintains a head office in Canada where it incurs expenses primarily denominated in Canadian dollars, such expenses are a small portion of overall expenses incurred by the Company. The Company does not have a practice of trading derivatives and does not engage in “natural hedging” for funds held in Canada.

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION As of March 31, 2023, the Company had two reportable segments as follows: • THC Cannabis – Cultivation, manufacturing, and distribution of THC cannabis; and • CBD Wellness – Sale of CBD products to third-party consumers. The below table presents financial results of each segment for the three months ended March 31, 2023 and 2022, as well as total assets as of March 31, 2023 and December 31, 2022: Three Months Ended March 31, 2023 2022 Net Revenues THC Cannabis $ 30,160 $ 25,783 CBD Wellness 216 265 Total Net Revenues $ 30,376 $ 26,048 Net (Income) Loss Attributable to Shareholders THC Cannabis $ 6,229 $ 2,467 CBD Wellness (14) (15) Corporate 5,182 3,447 Total Net Loss $ 11,397 $ 5,899 March 31, 2023 December 31, 2022 Assets THC Cannabis $ 332,257 $ 343,410 CBD Wellness 709 625 Corporate 780 697 Total Assets $ 333,746 $ 344,732

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS The Company has evaluated subsequent events through May 15, 2023, which is the date these consolidated interim financial statements were issued, and has concluded that the following subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes to the consolidated financial statements. In April 2023, the Company issued 2,308,952 Class A Subordinate Voting Shares valued at $0.4 million based on the closing stock price of the SVS on the issuance date as part of the Membership Interest Purchase Agreement to acquire Euphoria, LLC. Refer to Note 5 for additional discussion. In April 2023, the Board of Directors approved the settlement of $0.7 million of payables through the issuance of 4,062,500 Class A Subordinate Voting Shares to one of its service providers. The SVS shares were issued on May 10th at a price of $0.16 (or C$0.218) per share. The Board also approved a second payables settlement of an immaterial amount through the issuance of 625,000 purchase warrants of the Company (each, a "Warrant") to another service provider. Each Warrant will be exercisable at C$0.23 into one Class A Subordinate Voting Share for a period of four years.

Nature of Operations (Policies)

Nature of Operations (Policies)	3 Months Ended
Nature of Operations (Policies)	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no effect on the consolidated balance sheet and the consolidated statement of cash flows as of and for the year ended December 31, 2022. The reclassifications on the consolidated statement of operations for the year ended December 31, 2022 had no effect on revenues and net loss for the year ended December 31, 2022.
New Accounting Pronouncements	New Accounting Pronouncements Accounting Standard Updates Issued but Not Yet Adopted In June 2022, the FASB issued ASU 2022-03, "Fair Value Measurements - Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (Topic 820) ". ASU 2022-03 clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. It also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. For public business entities, the ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted and the amendments in the ASU should be applied prospectively with any adjustments from the adoption of the amendments recognized in earnings and disclosed on the date of adoption. The Company is currently assessing the impact of adopting ASU 2022-03 on the consolidated financial statements.

Inventory (Tables)

Inventory (Tables)	3 Months Ended
Inventory (Tables)	Mar. 31, 2023
Inventory Disclosure [Abstract]
Summary of Inventory	The Company’s inventories are summarized in the table below: March 31, 2023 December 31, 2022 Raw materials - unharvested cannabis $ 3,379 $ 2,688 Raw materials - harvested and purchased cannabis 7,760 7,956 Packaging and other non-finished goods 2,092 2,468 Work in process - manufactured and purchased extracts 3,980 3,635 Finished goods 10,177 8,845 Total inventory $ 27,388 $ 25,592

Property Plant and Equipment (T

Property Plant and Equipment (Tables)	3 Months Ended
Property Plant and Equipment (Tables)	Mar. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment and Related Depreciation	Property, plant, and equipment and related depreciation are summarized in the table below: March 31, 2023 December 31, 2022 Land $ 774 $ 774 Buildings & improvements 13,995 13,784 Construction in process 241 82 Furniture, equipment & other 19,000 19,296 Leasehold improvements 36,291 36,287 Total $ 70,301 $ 70,223 Less: accumulated depreciation (14,919) (13,317) Total property, plant, and equipment, net $ 55,382 $ 56,906

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended
Intangible Assets and Goodwill (Tables)	Mar. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Indefinite-Lived Intangible Assets	Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Compete Agreements Know-How Tradenames and Trademarks Total Gross Carrying Amount, March 31, 2023 and December 31, 2022 $ 25,662 $ 2,900 $ 249 $ 9,700 $ 2,022 $ 40,533 Accumulated Amortization, December 31, 2022 $ — $ (2,393) $ (249) $ (6,628) $ (336) $ (9,606) Amortization Expense — (145) — (485) (68) (698) Accumulated Amortization, March 31, 2023 $ — $ (2,538) $ (249) $ (7,113) $ (404) $ (10,304)
Schedule of Finite-Lived Intangible Assets	Intangible assets and related amortization are summarized in the table below: Licenses Customer Relationships Non-Compete Agreements Know-How Tradenames and Trademarks Total Gross Carrying Amount, March 31, 2023 and December 31, 2022 $ 25,662 $ 2,900 $ 249 $ 9,700 $ 2,022 $ 40,533 Accumulated Amortization, December 31, 2022 $ — $ (2,393) $ (249) $ (6,628) $ (336) $ (9,606) Amortization Expense — (145) — (485) (68) (698) Accumulated Amortization, March 31, 2023 $ — $ (2,538) $ (249) $ (7,113) $ (404) $ (10,304)

Leases (Tables)

Leases (Tables)	3 Months Ended
Leases (Tables)	Mar. 31, 2023
Leases [Abstract]
Direct Financing Lease, Lease Income	Lease income for operating and direct financing leases for the periods presented are as follows: Three Months Ended March 31, 2023 2022 Real estate income: Operating leases $ 2,384 $ 2,273 Direct financing leases 622 692 Total real estate income $ 3,006 $ 2,965
Balance Sheet Information	The underlying assets are presented in the condensed consolidated balances sheets as follows: March 31, 2023 December 31, 2022 Right-of-use assets $ 36,060 $ 36,596 Current portion of lease liability $ 1,610 $ 1,568 Long-term portion of lease liability $ 31,629 $ 31,904
Summary of Changes in Lease Receivables	A reconciliation of the lease receivables is as follows: March 31, 2023 December 31, 2022 Balance, December 31, 2022 $ 9,421 $ 10,378 Interest 621 2,673 Lease payments received (945) (3,630) Balance, March 31, 2023 9,097 9,421 Less current portion (3,855) (3,810) Long-term lease receivables $ 5,242 $ 5,611

Notes Payable and Convertible_2

Notes Payable and Convertible Notes (Tables)	3 Months Ended
Notes Payable and Convertible Notes (Tables)	Mar. 31, 2023
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s notes payable and convertible notes are as follows: Terms March 31, 2023 December 31, 2022 Secured promissory notes dated May 10, 2019, as subsequently amended, with a related party drawn in two tranches: (i) $35.0 million bearing interest at 12.75% and (ii) $10.0 million bearing interest at 14.75%, which mature on May 10, 2024 $ 50,129 $ 49,807 Convertible promissory note dated October 6, 2021, which mature on October 6, 2024 and bear interest at a rate of 6% per annum 15,122 14,843 Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 3,721 3,554 Promissory note issued for the acquisition of NECC due January 7, 2023 at 10% per annum — 519 Promissory note issued for the acquisition of Island due October 25, 2026 at 6% per annum 10,579 10,431 Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months (1) 2,254 3,230 Unsecured promissory note due September 30, 2023, monthly interest payments at 12% per annum 1,730 1,730 Various 43 51 Total Notes Payable and Convertible Notes $ 83,577 $ 84,165

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
Shareholders' Equity (Tables)	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Summary of Voting Shares Activity	Voting shares activity for the periods presented is summarized as follows: Class A Subordinate Voting Shares Class C Multiple Voting Shares Total Balance, December 31, 2022 642,140,067 1,276,208 643,416,275 Balance, March 31, 2023 642,140,067 1,276,208 643,416,275
Summary of Share Capital and Equity	Series Shares outstanding as of March 31, 2023 Class A - Subordinate Voting Shares 642,140,067 Class C - Multiple Voting Shares 1,276,208 643,416,275

Warrants (Tables)

Warrants (Tables)	3 Months Ended
Warrants (Tables)	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Summary of Warrants Outstanding to Purchase Shares	A reconciliation of the beginning and ending balance of share purchase warrants outstanding is as follows: Number of Warrants Weight-Average Exercise Price Balance, December 31, 2022 6,352,278 $ 0.82 Expired (2,227,303) 0.67 Balance, March 31, 2023 4,124,975 $ 0.89
Summary of Warrants Outstanding And Exercisable	As of March 31, 2023, the Company had the following warrants outstanding: Warrants Outstanding Exercise Price Expiration Date 2,999,975 $ 1.00 April 13, 2024 625,000 * C$ 0.80 October 6, 2024 500,000 * C$ 0.80 October 6, 2025 4,124,975 *Represents warrants that were exercisable as of March 31, 2023.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	3 Months Ended
Share-Based Compensation (Tables)	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Summary of Stock Option Activity	The following table summarizes the Company’s stock option activity and related information: Number of Options Weighted Average Price CAD$ Weighted Average Years Balance, December 31, 2022 75,626,960 $ 0.86 3.46 Forfeited/Expired (11,458,334) $ 0.65 — Balance, March 31, 2023 64,168,626 $ 0.83 2.94
Summary of Stock Options Values using Black-Scholes Model with Key Assumptions	In determining the amount of equity-based compensation during the period ended March 31, 2022, the Company used the Black-Scholes option pricing model to establish the fair value of options granted with the following key assumptions: Three Months Ended March 31, 2022 Risk-Free Interest Rate 2.42 % Expected Life 5.00 years Expected Annualized Volatility 71.30 % Forfeiture rate — % Expected Dividend Yield — %

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
Income Taxes (Tables)	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The following table summarizes the Company's income tax expense: For the Three Months Ended March 31, 2023 2022 Net loss before income taxes $ (8,326) $ (2,456) Income tax expense $ (3,066) $ (3,438)

Financial Instruments and Fin_2

Financial Instruments and Financial Risk Management (Tables)	3 Months Ended
	Mar. 31, 2023
Investments, All Other Investments [Abstract]
Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis	For the three months ended March 31, 2022, changes in fair value of the derivative liabilities measured on a recurring basis using significant unobservable inputs (Level 3) were as follows: For the Three Months Ended March 31, 2022 Balance, beginning of period $ 3,502 Gain on fair value of derivative liability (1,300) Balance, end of period $ 2,202
Schedule of Gross Contractual Obligations	The Company has the following gross contractual obligations as of March 31, 2023, which are expected to be payable in the following respective periods: Less than 1 year 1 to 3 years 3 to 5 years Greater than 5 years Total Accounts payable and accrued liabilities $ 23,701 $ 1,362 $ — $ — $ 25,063 Convertible notes, notes payable and accrued interest 7,727 75,850 — — 83,577 Construction finance liability — 16,000 — — 16,000 Total $ 31,428 $ 93,212 $ — $ — $ 124,640

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2023
Segment Reporting [Abstract]
Summary of Revenue By Type	The below table presents financial results of each segment for the three months ended March 31, 2023 and 2022, as well as total assets as of March 31, 2023 and December 31, 2022: Three Months Ended March 31, 2023 2022 Net Revenues THC Cannabis $ 30,160 $ 25,783 CBD Wellness 216 265 Total Net Revenues $ 30,376 $ 26,048 Net (Income) Loss Attributable to Shareholders THC Cannabis $ 6,229 $ 2,467 CBD Wellness (14) (15) Corporate 5,182 3,447 Total Net Loss $ 11,397 $ 5,899 March 31, 2023 December 31, 2022 Assets THC Cannabis $ 332,257 $ 343,410 CBD Wellness 709 625 Corporate 780 697 Total Assets $ 333,746 $ 344,732

Nature of Operations (Details)

Nature of Operations (Details) $ in Thousands	3 Months Ended
Nature of Operations (Details) $ in Thousands	Mar. 31, 2023 USD ($) Dispensary facility Segment	Mar. 31, 2022 USD ($)
Nature Of Operations [Line Items]
Number of operating segments \| Segment	2
Cash and cash equivalents	$ 4,600
Working capital deficit	29,000
Net loss	$ 11,392	$ 5,894
THC Cannabis
Nature Of Operations [Line Items]
Number of dispensaries \| Dispensary	6
Number of production facilities \| facility	7

Inventory - Summary of Inventor

Inventory - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Inventory [Line Items]
Packaging and other non-finished goods	$ 2,092	$ 2,468
Work in process - manufactured and purchased extracts	3,980	3,635
Finished goods	10,177	8,845
Total inventory	27,388	25,592
Raw materials - unharvested cannabis
Inventory [Line Items]
Raw materials	3,379	2,688
Raw materials - harvested and purchased cannabis
Inventory [Line Items]
Raw materials	$ 7,760	$ 7,956

Property Plant and Equipment -

Property Plant and Equipment - Summary of Property and Equipment and Related Depreciation (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 70,301	$ 70,223
Less: accumulated depreciation	(14,919)	(13,317)
Total property, plant, and equipment, net	55,382	56,906
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	774	774
Buildings & improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	13,995	13,784
Construction in process
Property, Plant and Equipment [Line Items]
Property and equipment, gross	241	82
Furniture, equipment & other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	19,000	19,296
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 36,291	$ 36,287

Property Plant and Equipment _2

Property Plant and Equipment - Additional Information (Details) - USD ($) $ in Millions		3 Months Ended
	Nov. 10, 2022	Mar. 31, 2023	Mar. 31, 2022	Oct. 27, 2022
Property, Plant and Equipment [Line Items]
Depreciation expense		$ 1.7	$ 1.2
Depreciation in COGS		$ 1.5	$ 0.9
IL Grown Medicine, LLC
Property, Plant and Equipment [Line Items]
Tenant improvement allowance, increase	$ 19.9
Remaining lease term	20 years
Increase in base rent	$ 0.2
Increase in security deposit	$ 2.2
IL Grown Medicine, LLC \| Minimum
Property, Plant and Equipment [Line Items]
Tenant improvement allowance, increase option				$ 15
IL Grown Medicine, LLC \| Maximum
Property, Plant and Equipment [Line Items]
Tenant improvement allowance, increase option				$ 19.9

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Indefinite-Lived and Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Roll Forward]
Accumulated amortization, beginning balance	$ (9,606)
Amortization Expense	(698)
Accumulated amortization, ending balance	(10,304)
Total
Intangible assets, gross	40,533	$ 40,533
Licenses
Indefinite-Lived Intangible Assets [Roll Forward]
Beginning balance	25,662
Ending balance	25,662
Customer Relationships
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	2,900
Ending balance	2,900
Accumulated amortization, beginning balance	(2,393)
Amortization Expense	(145)
Accumulated amortization, ending balance	(2,538)
Non-Compete Agreements
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	249
Ending balance	249
Accumulated amortization, beginning balance	(249)
Amortization Expense	0
Accumulated amortization, ending balance	(249)
Know-How
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	9,700
Ending balance	9,700
Accumulated amortization, beginning balance	(6,628)
Amortization Expense	(485)
Accumulated amortization, ending balance	(7,113)
Tradenames and Trademarks
Finite-Lived Intangible Assets [Roll Forward]
Beginning balance	2,022
Ending balance	2,022
Accumulated amortization, beginning balance	(336)
Amortization Expense	(68)
Accumulated amortization, ending balance	$ (404)

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill - Additional Information (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Disclosure Of Intangible Assets And Goodwill [Line Items]
Goodwill	$ 53,955,000	$ 53,955,000
THC Cannabis
Disclosure Of Intangible Assets And Goodwill [Line Items]
Accumulated impairment	0
CBD Wellness
Disclosure Of Intangible Assets And Goodwill [Line Items]
Accumulated impairment	$ 13,400,000

Asset Acquisitions - Additional

Asset Acquisitions - Additional Information (Details) - Euphoria, LLC - USD ($) $ in Millions			1 Months Ended
	Mar. 31, 2023	Mar. 27, 2023	May 15, 2023
Asset Acquisition [Line Items]
Asset acquisition, percentage of voting interests acquired		100%
Total purchase price		$ 4.5
Asset acquisition, total consideration		4.5
Payments for asset acquisitions	$ 0.3
Breakup fee in case of buyer termination		3.5
Breakup fee in case of seller termination		$ 3.5
Subsequent Event
Asset Acquisition [Line Items]
Asset acquisition, stock consideration (in shares)			2,308,952
Asset acquisition, consideration transferred, equity interest value			$ 0.4

Leases - Lease Income (Details)

Leases - Lease Income (Details) - USD ($) $ in Thousands	3 Months Ended
Leases - Lease Income (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Mar. 31, 2022
Leases [Abstract]
Operating leases	$ 2,384	$ 2,273
Direct financing leases	622	692
Total real estate income	$ 3,006	$ 2,965

Leases - Summary of Underlying

Leases - Summary of Underlying Assets Leased (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Leases [Line Items]
Right-of-use assets	$ 137,002	$ 138,451
Current portion of lease liability	3,742	4,479
Long-term portion of lease liability	137,503	136,185
Building
Leases [Line Items]
Right-of-use assets	36,060	36,596
Current portion of lease liability	1,610	1,568
Long-term portion of lease liability	$ 31,629	$ 31,904

Leases - Summary of Changes in

Leases - Summary of Changes in Lease Receivables (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Sales-type and Direct Financing Leases, Lease Receivable [Roll Forward]
Balance, December 31, 2022	$ 9,421	$ 10,378
Interest	621	2,673
Lease payments received	(945)	(3,630)
Balance, March 31, 2023	9,097	9,421
Less current portion	(3,855)	(3,810)
Long-term lease receivables	$ 5,242	$ 5,611

Notes Payable and Convertible_3

Notes Payable and Convertible Notes - Summary of Convertible Debt (Details)	Mar. 31, 2023 USD ($) tranche $ / shares	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Debt, net amount	$ 83,577,000	$ 84,165,000
Secured promissory notes dated May 10, 2019, as subsequently amended, with a related party drawn in two tranches: (i) $35.0 million bearing interest at 12.75% and (ii) $10.0 million bearing interest at 14.75%, which mature on May 10, 2024
Debt Instrument [Line Items]
Debt instrument, number of tranches \| tranche	2
Debt, net amount	$ 50,129,000	49,807,000
Secured Promissory Note, Tranche One
Debt Instrument [Line Items]
Debt instrument, face amount	$ 35,000,000
Interest rate, stated percentage	12.75%
Secured Promissory Note, Tranche Two
Debt Instrument [Line Items]
Debt instrument, face amount	$ 10,000,000
Interest rate, stated percentage	14.75%
Convertible promissory note dated October 6, 2021, which mature on October 6, 2024 and bear interest at a rate of 6% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage	6%
Debt, net amount	$ 15,122,000	14,843,000
Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price (in dollars per share) \| $ / shares	$ 0.50
Debt, net amount	$ 3,721,000	3,554,000
Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 \| Interest Rate, Period One
Debt Instrument [Line Items]
Interest rate, stated percentage	12%
Unsecured convertible promissory note at $0.50 per share due December 18, 2023 at 12% per annum through May 2023 and 14% per annum through December 2023 \| Interest Rate, Period Two
Debt Instrument [Line Items]
Interest rate, stated percentage	14%
Promissory note issued for the acquisition of NECC due January 7, 2023 at 10% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage	10%
Debt, net amount	$ 0	519,000
Promissory note issued for the acquisition of Island due October 25, 2026 at 6% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage	6%
Debt, net amount	$ 10,579,000	10,431,000
Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months
Debt Instrument [Line Items]
Debt, net amount	$ 2,254,000	3,230,000
Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months \| Interest Rate, Period One
Debt Instrument [Line Items]
Interest rate, stated percentage	1.50%
Secured promissory note due February 28, 2023 at 1.5% monthly interest for three months and 2% monthly interest for three months \| Interest Rate, Period Two
Debt Instrument [Line Items]
Interest rate, stated percentage	2%
Unsecured promissory note due September 30, 2023, monthly interest payments at 12% per annum
Debt Instrument [Line Items]
Interest rate, stated percentage	12%
Debt, net amount	$ 1,730,000	1,730,000
Various
Debt Instrument [Line Items]
Debt, net amount	$ 43,000	$ 51,000

Notes Payable and Convertible_4

Notes Payable and Convertible Notes - LI Lending LLC Additional Information (Details) - LI Lending LLC $ in Millions		1 Months Ended	3 Months Ended
	Apr. 30, 2020 USD ($)	Dec. 31, 2020	Mar. 31, 2023 USD ($) draw	Mar. 31, 2022 USD ($)	Jan. 01, 2022	May 10, 2019 USD ($)
Debt Instrument [Line Items]
Maximum borrowing capacity under credit facility						$ 50
Amount drawn			$ 43
Number of draws made \| draw			2
Percentage of exit fee of the principal balance			20%
Increase in interest rate		2.50%
Interest expense, debt			$ 1.9	$ 1.9
Repayments of debt			1.6	$ 1.5
LI Lending Facility, Draw One
Debt Instrument [Line Items]
Amount drawn	$ 33		$ 35
Interest rate			10.25%
Debt prepayment	$ 2
Interest rate on initial loan amount					12.75%
LI Lending Facility, Draw Two
Debt Instrument [Line Items]
Amount drawn			$ 10
Interest rate			12.25%
Interest rate on final loan amount					14.75%

Notes Payable and Convertible_5

Notes Payable and Convertible Notes - Convertible Notes Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Oct. 06, 2021
Debt Instrument [Line Items]
Loan discount accretion expense	$ 92	$ 0
October 2021 Convertible Note \| Convertible Note
Debt Instrument [Line Items]
Debt instrument, face amount				$ 15,000
Debt instrument, convertible, conversion price (in dollars per share)				$ 1.03
Interest rate, stated percentage				6%
Repayments of debt	1,100
Debt instrument, unamortized discount	$ 300		$ 400
Debt instrument, convertible, remaining discount amortization period	1 year 6 months		1 year 9 months
Interest expense, debt	$ 200	300
Loan discount accretion expense	$ 100	$ 100

Shareholders' Equity - Summary

Shareholders' Equity - Summary of Voting Shares Activity (Details)	Mar. 31, 2023 shares
Class Of Stock [Line Items]
Beginning balance (in shares)	643,416,275
Ending balance (in shares)	643,416,275
Class A Subordinate Voting Shares
Class Of Stock [Line Items]
Beginning balance (in shares)	642,140,067
Ending balance (in shares)	642,140,067
Class C Multiple Voting Shares
Class Of Stock [Line Items]
Beginning balance (in shares)	1,276,208
Ending balance (in shares)	1,276,208

Shareholders' Equity - Addition

Shareholders' Equity - Additional Information (Details) - Class C Multiple Voting Shares	3 Months Ended
	Mar. 31, 2023 vote
Class Of Stock [Line Items]
Number of votes each shareholder is entitled to for each share	800
Percentage of shares of one class held as a percentage of shares of another class	50%

Shareholders' Equity - Summar_2

Shareholders' Equity - Summary of Share Capital and Equity (Details) - shares	Mar. 31, 2023	Dec. 31, 2022
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	643,416,275	643,416,275
Class A Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	642,140,067
Class C Shares
Class Of Stock [Line Items]
Number of shares outstanding (in shares)	1,276,208

Warrants - Summary of Warrants

Warrants - Summary of Warrants Outstanding to Purchase Shares (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Number of Warrants
Number of warrants, beginning balance (in shares) \| shares	6,352,278
Number of warrants, expired (in shares) \| shares	(2,227,303)
Number of warrants, ending balance (in shares) \| shares	4,124,975
Weight-Average Exercise Price
Weighted average exercise price, Beginning balance (in dollars per share) \| $ / shares	$ 0.82
Weighted average exercise price, Expired (in dollars per share) \| $ / shares	0.67
Weighted average exercise price, Ending balance (in dollars per share) \| $ / shares	$ 0.89

Warrants - Summary of Warrant_2

Warrants - Summary of Warrants Outstanding And Exercisable (Details)	Mar. 31, 2023 $ / shares shares	Mar. 31, 2023 $ / shares shares	Dec. 31, 2022 shares
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	4,124,975	4,124,975	6,352,278
Exercise Price $1.00
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	2,999,975	2,999,975
Warrants purchase price per share (in dollar per share) \| $ / shares	$ 1
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	625,000	625,000
Warrants purchase price per share (in dollar per share) \| $ / shares		$ 0.80
Exercise Price CAD 0.80
Class Of Warrant Or Right [Line Items]
Warrants outstanding (in shares)	500,000	500,000
Warrants purchase price per share (in dollar per share) \| $ / shares		$ 0.80

Share-Based Compensation - Addi

Share-Based Compensation - Additional Information (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) plan shares	Mar. 31, 2022 USD ($)	Mar. 31, 2023 $ / shares shares	Dec. 31, 2022 shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans \| plan	2
Exercisable options (in shares)			51,999,458
Outstanding options (in shares)			64,168,626	75,626,960
Number of options, granted (in shares)	0
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike price (in dollar per share) \| $ / shares			$ 0.10
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Strike price (in dollar per share) \| $ / shares			$ 1.63
Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Recognized share-based compensation expense \| $	$ 1	$ 1
Class A Stock Options \| Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum number of stock options available for grant, percentage of number of outstanding shares	10%
Minimum exercise price of stock options issued, percentage of fair market value of shares on grant date	100%
Maximum term of stock options granted	10 years

Share-Based Compensation - Summ

Share-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Number of Options
Number of options, beginning balance (in shares)	75,626,960
Number of options, forfeited/ expired (in shares)	(11,458,334)
Number of options, ending balance (in shares)	64,168,626	75,626,960
Weighted Average Price CAD$
Weighted Average Price, Beginning Balance (in dollar per shares)	$ 0.86
Weighted Average Price, Forfeited/ Expired (in dollar per shares)	0.65
Weighted Average Price, Ending Balance (in dollar per shares)	$ 0.83	$ 0.86
Weighted Average Years
Weighted average years	2 years 11 months 8 days	3 years 5 months 15 days

Share-Based Compensation - Su_2

Share-Based Compensation - Summary of Stock Options Values using Black-Scholes Model with Key Assumptions (Details) - Share-Based Payment Arrangement, Option	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-Free Interest Rate	2.42%
Expected Life		5 years
Expected Annualized Volatility	71.30%
Forfeiture rate		0%
Expected Dividend Yield		0%

Income Taxes - Summary of Incom

Income Taxes - Summary of Income Tax Expense and Effective Tax Rates (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Net loss before income taxes	$ (8,326)	$ (2,456)
Income tax expense	$ (3,066)	$ (3,438)

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Thousands	3 Months Ended
Related Parties (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	May 10, 2019
Related Party Transaction [Line Items]
Debt, net amount	$ 83,577	$ 84,165
Chief Executive Officer \| LI Lending LLC
Related Party Transaction [Line Items]
Percentage of ownership interest held	14.28%
Director \| LI Lending LLC
Related Party Transaction [Line Items]
Percentage of ownership interest held	14.28%
LI Lending LLC Note, as Amended
Related Party Transaction [Line Items]
Maximum borrowing capacity under credit facility			$ 50,000
LI Lending LLC
Related Party Transaction [Line Items]
Maximum borrowing capacity under credit facility			$ 50,000
Long-term line of credit	$ 43,000
Line of credit facility, exit fee	9,000
Amount due at maturity	54,000
Long-term debt, gross	50,300
Debt instrument, unamortized discount	200
Debt, net amount	50,100
Interest payable	$ 7,300

Contingencies - Additional Info

Contingencies - Additional Information (Details) $ in Thousands	Jan. 26, 2022 USD ($) installment
Commitments and Contingencies Disclosure [Abstract]
Loss contingency damages sought value	$ 19,400
Loss contingency benefit value	129,000
Litigation settlement, amount	$ 250
Litigation settlement, number of installments \| installment	5

Financial Instruments and Fin_3

Financial Instruments and Financial Risk Management - Summary of Changes in Fair Value of the Derivative Liabilities Measured on a Recurring Basis (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2022 USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 3,502
Gain on fair value of derivative liability	(1,300)
Balance, end of period	$ 2,202

Financial Instruments and Fin_4

Financial Instruments and Financial Risk Management - Additional information (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Investments, All Other Investments [Abstract]
Cash, uninsured amount	$ 0.7	$ 10.1
Maximum credit exposure	$ 17.8	$ 16.9

Financial instruments and fin_5

Financial instruments and financial risk management - Schedule of Gross Contractual Obligations (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Financial Instruments [Line Items]
Less than 1 year	$ 31,428
1 to 3 years	93,212
3 to 5 years	0
Greater than 5 years	0
Total	124,640
Accounts payable and accrued liabilities
Financial Instruments [Line Items]
Less than 1 year	23,701
1 to 3 years	1,362
3 to 5 years	0
Greater than 5 years	0
Total	25,063
Convertible notes, notes payable and accrued interest
Financial Instruments [Line Items]
Less than 1 year	7,727
1 to 3 years	75,850
3 to 5 years	0
Greater than 5 years	0
Total	83,577
Construction finance liability
Financial Instruments [Line Items]
Less than 1 year	0
1 to 3 years	16,000
3 to 5 years	0
Greater than 5 years	0
Total	$ 16,000

Segment Information - Additiona

Segment Information - Additional Information (Details)	3 Months Ended
Segment Information - Additional Information (Details)	Mar. 31, 2023 Segment
Segment Reporting [Abstract]
Number of reportable segments	2

Segment Information - Summary o

Segment Information - Summary of Revenues By Type (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total Net Revenues	$ 30,376	$ 26,048
Total Net Loss	11,397	5,899
Total Assets	333,746		$ 344,732
Operating Segments \| THC Cannabis
Segment Reporting Information [Line Items]
Total Net Revenues	30,160	25,783
Total Net Loss	6,229	2,467
Total Assets	332,257		343,410
Operating Segments \| CBD Wellness
Segment Reporting Information [Line Items]
Total Net Revenues	216	265
Total Net Loss	(14)	(15)
Total Assets	709		625
Corporate
Segment Reporting Information [Line Items]
Total Net Loss	5,182	$ 3,447
Total Assets	$ 780		$ 697

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	May 15, 2023 USD ($) shares	Apr. 30, 2023 USD ($) $ / shares shares	Apr. 30, 2023 $ / shares	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Subsequent Event [Line Items]
Debt payable \| $				$ 83,577	$ 84,165
Subsequent Event
Subsequent Event [Line Items]
Liabilities settled through issuance of stock \| $		$ 700
Stock issued to settle liabilities (in shares) \| shares		4,062,500
Units issued, price per unit (in dollar per share) \| (per share)		$ 0.16	$ 0.218
Issuance of warrant purchase (in shares) \| shares		625,000
Warrants purchase price per share (in dollar per share) \| $ / shares			$ 0.23
Warrant term		4 years
Euphoria, LLC \| Subsequent Event
Subsequent Event [Line Items]
Asset acquisition, stock consideration (in shares) \| shares	2,308,952
Asset acquisition, consideration transferred, equity interest value \| $	$ 400